Wellesley Investment Partners LLC bought a new stake in Amgen Inc. (NASDAQ:AMGN) during the third quarter, Holdings Channel reports. The fund bought 2,885 shares of the medical research company’s stock, valued at approximately $481,000.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. New York Life Trust Co. boosted its position in Amgen by 54.8% in the third quarter. New York Life Trust Co. now owns 624 shares of the medical research company’s stock worth $104,000 after buying an additional 221 shares during the last quarter. Penserra Capital Management LLC boosted its position in Amgen by 100.0% in the third quarter. Penserra Capital Management LLC now owns 684 shares of the medical research company’s stock worth $114,000 after buying an additional 342 shares during the last quarter. Oakworth Capital Inc. boosted its position in Amgen by 1.4% in the third quarter. Oakworth Capital Inc. now owns 711 shares of the medical research company’s stock worth $119,000 after buying an additional 10 shares during the last quarter. Valley National Advisers Inc. boosted its position in Amgen by 4.8% in the second quarter. Valley National Advisers Inc. now owns 714 shares of the medical research company’s stock worth $109,000 after buying an additional 33 shares during the last quarter. Finally, Nelson Roberts Investment Advisors LLC bought a new position in Amgen during the third quarter worth $123,000. 79.01% of the stock is currently owned by institutional investors and hedge funds.
Amgen Inc. (NASDAQ:AMGN) traded up 2.80% during trading on Friday, reaching $157.26. The company had a trading volume of 429,859 shares. The firm has a market capitalization of $116.99 billion, a price-to-earnings ratio of 15.74 and a beta of 1.14. Amgen Inc. has a 52 week low of $133.64 and a 52 week high of $176.85. The company’s 50-day moving average is $150.60 and its 200 day moving average is $159.41.
Amgen (NASDAQ:AMGN) last released its earnings results on Thursday, October 27th. The medical research company reported $3.02 earnings per share for the quarter, beating the consensus estimate of $2.79 by $0.23. The business had revenue of $5.81 billion for the quarter, compared to the consensus estimate of $5.73 billion. Amgen had a return on equity of 29.27% and a net margin of 33.63%. The business’s quarterly revenue was up 1.5% compared to the same quarter last year. During the same quarter last year, the business posted $2.72 earnings per share. Equities analysts anticipate that Amgen Inc. will post $11.55 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Wednesday, March 8th. Stockholders of record on Wednesday, February 15th will be given a $1.15 dividend. This represents a $4.60 annualized dividend and a dividend yield of 3.01%. The ex-dividend date is Monday, February 13th. This is an increase from Amgen’s previous quarterly dividend of $1.00. Amgen’s dividend payout ratio (DPR) is 39.92%.
A number of research analysts have recently weighed in on the company. Oppenheimer Holdings, Inc. set a $166.00 price objective on Amgen and gave the company a “buy” rating in a research report on Friday. RBC Capital Markets set a $190.00 price objective on Amgen and gave the company a “buy” rating in a research report on Sunday, October 30th. Vetr cut Amgen from a “strong-buy” rating to a “buy” rating and set a $157.82 price objective on the stock. in a research report on Monday, December 5th. Chardan Capital raised Amgen from a “sell” rating to a “neutral” rating in a research report on Tuesday, December 13th. Finally, Robert W. Baird reaffirmed a “neutral” rating and set a $165.00 price objective (up from $157.00) on shares of Amgen in a research report on Sunday, January 8th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $179.48.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).